Issued: Sep-30-2015

# ODOVIE SAFETY DATA SHEET

# Section 1. Identification of the substance/mixture and of the company/undertaking

1.1 Product Identifier

**Product Name:** Dasabuvir Film-Coated Tablets (ANZ)

**Synonyms:** Dasabuvir film-coated tablets 250 mg; Dasabuvir tablets; Exviera tablets; Viekira

Pak; Holkira Pak

**List Number:** 3075; kit: 3093

1.2 Relevant identified uses of the substance or mixture and uses advised against

**Recommended use:** Pharmaceuticals

1.3 Details of the supplier of the safety data sheet

**Supplier:** AbbVie

L1, 32-34 Lord St. Botany, NSW 2019

Australia

**Customer Service Telephone:** 1800 043 460 (AU)

0800 900 030 (NZ)

**E-mail Address:** medinfoanz@abbvie.com

1.4 Emergency telephone number

**Emergency Telephone:** 1800 043 460 (AU)

0800 900 030 (NZ)

# Section 2. Hazards identification

2.1 Classification of the substance or mixture

**Regulation (EC) No 1272/2008** 

**Chronic aquatic toxicity** Chronic toxicity 4

Classification according to EU Directives 67/548/EEC or 1999/45/EC

**Risk Phrases:** R53 - May cause long-term adverse effects in the aquatic environment

2.2 Label elements

**Hazard Statements:** H413 - May cause long lasting harmful effects to aquatic life

2.3 Other hazards

Not determined

Section 3. Composition/information on ingredients

**Issued:** Sep-30-2015

Chemical Name	Percent	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH No.
Dasabuvir Sodium	30-50	NA		Aquatic Chronic Cat. 4 (H413)	No data available
Cellulose Microcrystalline 9004-34-6	20-40	Present		Not Hazardous*	No data available
Copovidone 25086-89-9	5-20	NA		Not Hazardous*	No data available
Lactose monohydrate 10039-26-6	5-20	NA		Not Hazardous*	No data available
Croscarmellose sodium 74811-65-7	1-10	NA		Not Hazardous*	No data available
Magnesium Stearate 557-04-0	1-10	Present		Not Hazardous*	No data available

Not Hazardous\* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

For the full text of the R-phrases mentioned in this Section, see Section 16

For the full text of the H-Statements mentioned in this Section, see Section 16

## Section 4. First aid measures

### 4.1 Description of first aid measures

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic/supportive care as necessary.

**Protection of First-aiders:** Use personal protective equipment

### 4.2 Most important symptoms and effects, both acute and delayed

**Signs and Symptoms:** None known from occupational exposure.

**Medical Conditions** 

None known from occupational exposure.

**Aggravated by Exposure:** 

## 4.3 Indication of any immediate medical attention and special treatment needed

**Notes To Physician:** Treat symptomatically

# Section 5. Firefighting measures

### 5.1 Extinguishing Media

Issued: Sep-30-2015

**Suitable Extinguishing Media:** Use extinguishing agent suitable for type of surrounding fire

Unsuitable Extinguishing Media: Not determined

## 5.2 Special hazards arising from the substance or mixture

**Special Exposure Hazards:** Not determined

**5.3** Advice for firefighters

Protective Equipment and Precautions for Firefighters:

As in any fire, wear self-contained breathing apparatus and full protective gear

## Section 6. Accidental release measures

## 6.1. Personal precautions, protective equipment and emergency procedures

**Personal Precautions:** For personal protection see section 8.

**6.2.** Environmental precautions

**Environmental Precautions:** Contain material and prevent release to waterways or soil.

6.3. Methods and material for containment and cleaning up

**Methods for Cleaning Up:** Recover product and place in an appropriate container for disposal.

6.4. Reference to other sections

Refer to Sections 8, 12, and 13 for further information.

# Section 7. Handling and storage

### 7.1. Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

Store according to label instructions.

## 7.3. Specific end use(s)

**Recommended use:** Pharmaceuticals

# Section 8. Exposure controls/personal protection

### **8.1.** Control parameters

### **Exposure limits:**

Chemical Name	Employee Exposure Limit	Skin Notation
Dasabuvir Sodium	80 mcg/m <sup>3</sup>	None
Cellulose Microcrystalline 9004-34-6	Not Applicable	None

**Issued:** Sep-30-2015

Copovidone 25086-89-9	Not Applicable	None
Lactose monohydrate 10039-26-6	Not Applicable	None
Croscarmellose sodium 74811-65-7	Not Applicable	None
Magnesium Stearate 557-04-0	Not Applicable	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Cellulose Microcrystalline 9004-34-6	10 mg/m³ TWA	TWA: 10 mg/m <sup>3</sup>		20 mg/m³ (STEL) 12 mg/m³ (STEL) 10 mg/m³ (TWA) 4 mg/m³ (TWA)	
Magnesium Stearate 557-04-0	10 mg/m³ total dust				

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Cellulose Microcrystalline 9004-34-6		10 mg/m³ (TWA)	3 mg/m³ (TWA)	20 mg/m³ (STEL) 12 mg/m³ (STEL) 10 mg/m³ (TWA) 4 mg/m³ (TWA)

#### 8.2. Exposure controls

**Engineering Controls:** No special provisions are required under normal product use conditions.

Use inside a process enclosure when handling the bulk formulation.

**Respiratory Protection:** Respiratory protection is not needed during normal product use. When handling

the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be

worn when exposures are expected to exceed the applicable limits.

**Eyes:** Eye protection not needed during typical product use conditions. Wear eye

protection as appropriate when handling the bulk formulation.

Gloves: Gloves not required during normal product use conditions. Wear impervious

gloves when handling the bulk formulation.

Other PPE Data: Not needed during normal product use. Wear appropriate body coverings if

contact may occur.

**Environmental Exposure** 

**Controls:** 

Not determined

# Section 9. Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

Appearance: Beige Ovaloid tablet Odor: Not determined. **Odor Threshold:** Not determined Not determined. **Boiling Pt.** @ **760 mm Hg** (°C): Not determined. **Melting/Freezing Point (°C):** Not determined Flash Point (°C): Not determined. **Evaporation Rate at 20°C:** Not determined. Flammability (Solid): Not determined. **Lower Explosive Limit:** Not determined. **Upper Explosive Limit:** Not determined.

Issued: Sep-30-2015

Vapor Pressure (mm Hg):Not determined.Vapor Density (Air = 1):Not determined.Specific Gravity:Not determined.Solubility(ies):Not determined.Partition coefficient:Not determined.

n-octanol/water

**Autoignition Temp.** (°C): Not determined. **Decomposition temperature** Not determined.

(°C):

Viscosity (centipoise):

Explosion Severity:

Oxidizer Properties:

Not determined.

Not determined.

Not determined.

#### **9.2.** Other information

Not determined

Maximum Pressure Rise (bar): 6.9 Max. rate of pressure rise 407

(bar/sec):

Kst Value (bar.m/s): 110 Min. Ignition Energy-Cloud > 1000

(mJ):

Min. Ignit. Temp. Dust Cloud 600

(°C):

Min. Explosive Conc. (g/m<sup>3</sup>): 80

# Section 10. Stability and reactivity

#### 10.1. Reactivity

Not determined

### **10.2.** Chemical stability

Stable under normal conditions

#### 10.3. Possibility of hazardous reactions

**Hazardous reactions:** Not determined.

#### 10.4. Conditions to avoid

Not determined.

### 10.5 Incompatible materials

Not determined

## 10.6 Hazardous decompostion products

Not determined

# Section 11. Toxicological information

#### 11.1. Information on toxicological effects

**Issued:** Sep-30-2015

**Routes of Exposure:** 

Oral: Clinical Route

**Dermal:** Yes **Inhalation:** Unlikely

**Acute Toxicity - Oral:** Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LD50 >	5000	mg/kg	Rats
Copovidone 25086-89-9	LD50 >	630	mg/kg	Rats
Lactose monohydrate 10039-26-6	LD50 >	10000	mg/kg, for a similar material	Rats

Acute Toxicity - Dermal: Data for component (s) given below.

Chemical Name	Acute Test	Value	Units	Species
Cellulose Microcrystalline	LD50 >	2000	mg/kg	Rabbits
9004-34-6				

**Acute Toxicity - Inhalation:** Data for component (s) given below.

Chemical Name	Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LC 50 >	5800	mg/m³ , 4 hour	Rats
Magnesium Stearate 557-04-0	LC 50 >	2000	mg/m³, 1 hour	Rats

Corrosivity: Not determined.

**Dermal Irritation:** Not determined.

**Eye Irritation:** Not determined.

**Sensitization:** Not determined.

**Toxicokinetics/Metabolism:** Not determined.

**Target Organ Effects:** Data for component (s) given below.

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Dasabuvir Sodium	None	Rats	800	mg/kg	Oral	6 months
		Dogs	60			once weekly for 3
		Monkeys	150			weeks
						28 days

**Reproductive Effects:** Not determined.

Carcinogenicity: Not determined.

**Mutagenicity:** Data for component (s) given below.

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Dasabuvir Sodium	No Data.	Negative	Negative	Negative
Lactose monohydrate 10039-26-6	No Data.	Negative	No Data.	Negative
Magnesium Stearate 557-04-0	No Data.	Negative	No Data.	No Data.

**Aspiration hazard:** Not determined

Issued: Sep-30-2015

**Notes:** 

1. ALD: Approximate lethal dosage

2. LC50: Concentration in air that produces 50% mortality

3. LD50: Oral or dermal dosage that produces 50% mortality

# Section 12. Ecological information

### 12.1. Toxicity

Data for component (s) given below. No aquatic toxicity detected at the limit of solubility

Percent	LC 50 (mg/l)	Species	Duration
30-50	> 0.80	Lepomis macrochirus	96 Hours

Chemical Name	Percent	72h IC50 (algae - mg/l) (72HICA)	Species	Duration
Dasabuvir Sodium	30-50	> 0.55	Pseudokirchneriella subcapitata	72 Hours

### 12.2. Persistence and degradability

Data for component (s) given below.

Chemical Name	Percent	% Degradation	Duration
Dasabuvir Sodium	30-50	0.4	28 days

### 12.3. Bioaccumulative potential

Data for components given below.

Chemical Name	Percent	Log Po/w
Dasabuvir Sodium	30-50	4.23

### 12.4. Mobility in soil

Not determined.

#### 12.5. Results of PBT or vPvB assessment

Chemical safety report is not required for this substance/product.

### 12.6. Other adverse effects

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

#### **Notes:**

- 1. EC50: Concentration in water that produces 50% mortality in Daphnia sp.
- 2. LC50: Concentration in water that produces 50% mortality in fish.
- 3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

# Section 13. Disposal considerations

### 13.1 Waste treatment methods

Waste Disposal Methods: Disposal should be made in accordance with country, federal, state and local

regulations.

# Section 14. Transport information

Issued: Sep-30-2015

## ADR, DOT, ICAO/IATA, IMDG/IMO

Status: Not regulated

14.1. UN Number: Not applicable
14.2. Proper shipping name: Not applicable
14.3. Hazard class: Not applicable
14.4. Packing group: Not applicable
14.5. Environmental hazard: Not applicable
14.6. Special Provisions: Not applicable
14.7. Transport in bulk

according to Annex II of MARPOL 73/78 and the IBC

**Code:** 

# Section 15. Regulatory Information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

### **International Inventories**

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Dasabuvir Sodium	-	-	-	Not listed.	-
Cellulose Microcrystalline 9004-34-6	Present	X	X	Not listed.	X
Copovidone 25086-89-9	-	X	X	Not listed.	X
Lactose monohydrate 10039-26-6	-	-	-	Not listed.	-
Croscarmellose sodium 74811-65-7	-	-	-	Not listed.	X
Magnesium Stearate 557-04-0	Present	X	X	Not listed.	X

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Dasabuvir Sodium	-	-	-	-	-	
Cellulose Microcrystalline 9004-34-6	Present	-	X	X	Present	
Copovidone 25086-89-9	Present	-	X	X	Present	
Lactose monohydrate 10039-26-6	-	-	X	-	-	
Croscarmellose sodium 74811-65-7	-	-	X	X	-	
Magnesium Stearate 557-04-0	Present	-	X	X	Present	

### Legend

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

ISHL - Japan Industrial Safety and Health Law

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

### **Carcinogenicity Rating:**

**Issued:** Sep-30-2015

Chemical Name	Percent	NTP:	IARC:	ACGIH:
Dasabuvir Sodium	30-50	Not Listed	Not Listed	Not Listed
Cellulose Microcrystalline	20-40	Not Listed	Not Listed	Not Listed
Copovidone	5-20	Not Listed	Not Listed	Not Listed
Lactose monohydrate	5-20	Not Listed	Not Listed	Not Listed
Croscarmellose sodium	1-10	Not Listed	Not Listed	Not Listed
Magnesium Stearate	1-10	Not Listed	Not Listed	Not Listed

### **SARA 313 Information**

Chemical Name	Percent	SARA 313 Chemical:	CERCLA RQ/SARA	SARA EHS TPQ
			EHS RQ (lbs):	(lbs):
Dasabuvir Sodium	30-50	No	Not Applicable	Not applicable
Cellulose Microcrystalline	20-40	No	Not Applicable	Not applicable
Copovidone	5-20	No	Not Applicable	Not applicable
Lactose monohydrate	5-20	No	Not Applicable	Not applicable
Croscarmellose sodium	1-10	No	Not Applicable	Not applicable
Magnesium Stearate	1-10	No	Not Applicable	Not applicable

Immediate Health:YesDelayed Health:NoFire:NoSudden Pressure:NoReactivity:No

**RCRA Status:** Not determined.

**Proposition 65 Status:** Does not contain chemicals known to the state of California to cause cancer or

reproductive harm.

WHMIS Hazard Class: Not determined.

**NFPA Rating:** 

Health: 1 Fire: 1 Reactivity: 0

**Notes:** 

- 1. SARA = Superfund Amendments and the Reauthorization Act.
- 2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
- 3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
- 4. TSCA = Toxic Substances Control Act.
- 5. EC = European Community.
- 6. WHMIS = Canadian Workplace Hazardous Materials Information System.
- 7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

#### 15.2. Chemical safety assessment

Chemical safety assessment has not been conducted on the substance/product.

# Section 16. Other information

### **Risk Phrases:**

R53 - May cause long-term adverse effects in the aquatic environment

#### Full text of H-Statements referred to under sections 2 and 3

H413 - May cause long lasting harmful effects to aquatic life

**Document Authored By:** Occupational and Environmental Toxicology

**Issued:** Sep-30-2015

Page 9 of 10

Product Name: Dasabuvir Film-Coated Tablets (ANZ)
Issued: Sep-30-2015

### Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.